Hoek, K G., H. S. Schaaf, N. C. Gey van Pittius, P. D. van Helden, and R. M. Warren. 2009. Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment. South African Medical Journal 99(11):785-787.

IOM (Institute of Medicine). 2009. Addressing the threat of drug-resistant tuberculosis: A realistic assessment of the challenge: Workshop summary. Washington, DC: The National Academies Press.

IOM. 2011. The emerging threat of drug-resistant tuberculosis in Southern Africa: Global and local challenges and solutions: Workshop summary. Washington, DC: The National Academies Press.

Johnson, R., A. M. Jordaan, L. Pretorius, E. Engelke, G. van der Spuy, C. Kewley, M. Bosman, P. D. van Helden, R. Warren, and T. C. Victor. 2006. Ethambutol resistance testing by mutation detection. International Journal of Tuberculosis and Lung Disease 10(1):68-73.

Keshavjee, S., and K. Seung. 2008. Stemming the tide of multidrug-resistant tuberculosis: Major barriers to addressing the growing epidemic. http://www.iom.edu/~/media/Files/Activity%20Files/Research/DrugForum/IOM_MDRTB_whitepaper_2009_01_14_FINAL_Edited.pdf (accessed August 30, 2010).

Kuzmin, A. V., I. A. Vasileva, and L. N. Chernousova. 2006. Efficiency of chemotherapy of destructive pulmonary tuberculosis, based on the results of rapid detection of drug sensitivity to isoniazid and rifampicin with the “TB-Biochip” test system. Probl Tuberk Bolezn Legk (8):17-23.

Li, R. 2010. Surveillance for Anti-Tuberculosis Drug Resistance in China. Speaker presentation at the Institute of Medicine Workshop on The New Profile of Drug-Resistant Tuberculosis: A Global and Local Perspective, May 26, Moscow, Russian Federation.

Llerena, C., S. E. Fadul, M. C. Garzón, G. Mejía, D. L. Orjuela, L. M. García, H. B. Álvarez, and F. J. Ruiz. 2010. Drug-resistant Mycobacterium tuberculosis in children under 15 years. Biomedica 30(3):362-370.

Louw, G. E., R. M. Warren, P. R. Donald, M. B. Murray, M. Bosman, P. D. Van Helden, D. B. Young, and T. C. Victor. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. International Journal of Tuberculosis and Lung Disease 10(7):802-807.

Mlambo, C. K., R. M. Warren, X. Poswa, T. C. Victor, A. G. Duse, and E. Marais. 2008. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. International Journal of Tuberculosis and Lung Disease 12(1):99-104.

Morozova, T. I. 2008 (unpublished). Experience of MDR TB treatment in Saratov region. Presented at 1st Scientific Practical Conference “Problems of diagnostics and treatment of MDR and XDR tuberculosis,” Central Institute for Tuberculosis, Russian Academy of Medical Sciences, December 18-19, 2008.

Mphahlele, M., H. Syre, H. Valvatne, R. Stavrum, T. Mannsåker, T. Muthivhi, K. Weyer, P. B. Fourie, and H. M. Grewal. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. Journal of Clinical Microbiology 46(10):3459-3464.

Nardell, E., B. McGinnis, B. Thomas, and S. Weidhaas. 1986. Exogenous reinfection with tuberculosis in a shelter for the homeless. New England Journal of Medicine 315:1570-1575.

Nugent, R., E. Back, and A. Beith. 2010. The race against drug resistance: A report of the Center for Global Development’s Drug Resistance Working Group. http://www.cgdev.org/content/publications/detail/1424207/ (accessed August 19, 2010).

Perelman, M. I. 2000. Tuberculosis in Russia. International Journal of Tuberculosis and Lung Disease 4(12):1097-1103.

PIH (Partners In Health). 2010. Socios En Salud project history. http://www.pih.org/pages/peru-history# (accessed August 31, 2010).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement